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KEY POINTS 
Question: Is a single transdiagnostic psychological treatment, the Unified Protocol (UP), 
at least as effective as various well-established single-disorder protocols (SDPs) in the 
treatment of various anxiety disorders? 
Findings: In this randomized controlled equivalence trial of 223 adults, treatment with 
the UP produced reductions in symptom severity for four different anxiety disorders that 
were statistically equivalent to SDPs both at acute outcome and at 6-month follow-up. 
Meaning: The UP, a transdiagnostic intervention consisting of five core modules, may 
produce effects comparable to SDPs targeting individual disorders, thereby facilitating 
dissemination and increasing access to these treatments.  
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ABSTRACT 
Importance: Transdiagnostic interventions have been developed to address barriers to 
the dissemination of evidence-based psychological treatments (EBPTs), but only a few 
preliminary studies have compared these approaches to existing EBPTs. 
Objective: To determine whether the Unified Protocol (UP) is at least as efficacious as 
single-disorder protocols (SDPs) in the treatment of anxiety disorders. 
Design: From May 2011 to March 2015, 223 patients were randomly assigned by 
principal diagnosis to the UP, a SDP, or a waitlist control (WLC) condition. Patients 
received up to 16 sessions of the UP or a SDP over 16-21 weeks. Outcomes were 
assessed at baseline, posttreatment, and 6-month follow-up. Analysis in this equivalence 
trial was based on intention to treat. 
Setting: Outpatient treatment center. 
Participants: Patients with a principal diagnosis of panic disorder with or without 
agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, or social 
anxiety disorder were eligible for the study. Exclusions included conditions requiring 
treatment prioritization or a prior course of cognitive-behavior therapy.  
Interventions: UP or SDPs. 
Main Outcomes and Measures: Blind evaluations of principal diagnosis clinical 
severity rating (CSR) were used to evaluate an a priori hypothesis of equivalence 
between the UP and SDPs.  
Results: Among the 223 patients (124 women [56%]; 99 men [44%]; mean [SD] age, 
31.1 [11.0] years), 88 were randomized to the UP, 91 to a SDP, and 44 to the WLC 
condition. Patients were more likely to complete treatment with the UP than SDPs (odds 
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ratio, 3.11; 95% CI, 1.44 to 6.74). Both UP (Cohen’s d, -0.93; 95% CI, -1.29 to -0.57) 
and SDPs (Cohen’s d, -1.08; 95% CI, -1.43 to -0.73) were superior to WLC at acute 
outcome. Reductions in CSR from baseline to posttreatment (b, 0.25; 95% CI, -0.26 to 
0.75) and 6-month follow-up (b, 0.16; 95% CI, -0.39 to 0.70) indicated statistical 
equivalence between the UP and SDPs.  
Conclusions and Relevance: The UP produces symptom reduction equivalent to gold 
standard EBPTs for anxiety disorders with less attrition. Thus, it may be possible to 
utilize one protocol instead of multiple SDPs to more efficiently treat the most commonly 
occurring anxiety and depressive disorders.  
Trial Registration: clinicaltrials.gov identifier: NCT01243606 
Word count: 346 
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INTRODUCTION 
Despite the development of robust evidence-based psychological treatments 
(EBPTs) for anxiety, mood, and related “emotional” disorders (J. R. Bullis et al., 
unpublished data), the public health impact of these interventions has been limited.1-4 
Two of the foremost barriers to widespread dissemination and implementation of EBPTs 
are the burden associated with training clinicians to competently administer different 
manual-based interventions for each individual anxiety, depressive, or related disorder 
(single-disorder protocols; SDPs) and the criticism that these protocols lack external 
validity.5-7 For this reason, in a recent report the Institute of Medicine (IOM; now the 
National Academy of Medicine) recommended increased emphasis on further 
development, dissemination, and implementation of EBPTs. One approach is to develop 
interventions applicable to several related disorders (transdiagnostic8,9) based on theory 
or empirical grounds 10, 11 and initial results have been promising12-16. The Unified 
Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)17 is an emotion-
focused, cognitive-behavioral intervention consisting of five core modules or components 
that target temperamental characteristics, particularly neuroticism and resulting emotion 
dysregulation, underlying all anxiety, depressive, and related disorders.18,19 By addressing 
shared mechanisms associated with neuroticism, specifically negative evaluation and 
avoidance of intense emotional experience20, this approach could simplify training efforts 
while also addressing concerns about generalizability to routine care settings by 
simultaneously accommodating comorbid emotional disorders. Such an approach may 
increase access to EBPTs for the most common psychiatric disorders. 
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After developing preliminary support for the efficacy of the UP for the treatment 
of anxiety and comorbid depressive disorders,21,22 it was important to determine the 
relative efficacy of this approach compared to well-established SDPs, which are currently 
first line treatments in extant clinical practice guidelines.23,24 We hypothesized that the 
UP would be at least as efficacious as SDPs at acute outcome and at six months following 
treatment when delivered to a heterogeneous group of patients with principal anxiety 
disorders and diverse comorbidities. 
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STUDY DESIGN 
Participants 
A sample of 223 patients was recruited from treatment-seeking individuals at the 
Center for Anxiety and Related Disorders at Boston University (CARD). The study was 
approved by the institutional review board of Boston University and written informed 
consent was obtained prior to any research activity. Recruitment was designed to be 
broadly inclusive. Individuals were eligible for the study if they were 1) assigned a 
principal (most interfering and severe) diagnosis of panic disorder with or without 
agoraphobia (PD/A), generalized anxiety disorder (GAD), obsessive-compulsive disorder 
(OCD), or social anxiety disorder (SAD); 2) 18 years or older; and 3) fluent in English. 
Following long-standing procedures in our clinical trials, individuals taking psychotropic 
medications at the time of enrollment were required to be stable on the same dose for at 
least six weeks prior to enrolling in the study, and were requested to maintain these 
medications and dosages during treatment.  
Exclusion criteria consisted primarily of conditions that required prioritization for 
immediate or simultaneous treatment: specifically, a current diagnosis of bipolar disorder, 
schizophrenia, schizoaffective disorder, or organic mental disorder; current high suicide 
risk; or recent (within three months) history of substance use disorder, with the exception 
of nicotine (1 patient), marijuana (0 patients), and caffeine (0 patients). Individuals were 
also excluded if they had received at least eight sessions of cognitive-behavioral therapy 
(CBT) within the past five years. Anyone receiving non-CBT psychotherapy focused on 
an emotional disorder agreed to discontinue that treatment. 
Procedures 
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Figure 1 depicts the study design and summarizes patient flow. The study 
consisted of two phases: 1) a 16-session acute treatment (12 sessions for patients with a 
principal diagnosis of PD/A) or 16-week waitlist control (WLC) phase; and 2) a 6-month 
follow-up phase (WLC patients were not included in the follow-up phase of the study). 
The acute treatment phase was limited to a maximum of 21 weeks (16 weeks for PD/A). 
If patients were unable to complete the full course of treatment during the specified 
treatment window, treatment was terminated and follow-up assessments were conducted.  
Randomization and Blinding 
Patients were randomized by principal diagnosis (PD/A, GAD, OCD, and SAD) 
using a computerized block randomization with a 2:2:1 allocation ratio to UP, SDP, and 
WLC study conditions, respectively. The project coordinator was unaware of these 
assignments until after each patient was deemed eligible for the study and consented. 
Patients were unaware of study hypotheses and were instructed not to reveal their 
randomization status to raters prior to each assessment. To further protect blinding, raters 
were located separately from therapists and a new rater was assigned in the event of an 
accidental unblinding.   
Interventions 
Number and length of treatment sessions were based on each SDP’s 
recommended dose of treatment as described below. Treatment dosage for the UP was 
matched to each principal diagnosis’ corresponding SDP so that there were no differences 
between the active treatment conditions in the amount of treatment patients received. 
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Single-Disorder Protocols 
The SDPs included: Managing Social Anxiety: A Cognitive-Behavioral Therapy 
Approach – 2nd edition (MSA-II);25,26 Mastery of Your Anxiety and Panic – 4th edition 
(MAP-IV);27.28 Mastery of Your Anxiety and Worry – 2nd edition (MAW-II);29,30 and 
Treating Your OCD with Exposure and Response (Ritual) Prevention Therapy – 2nd 
edition.31-33 As recommended by the protocol developers, patients with a principal 
diagnosis of SAD, GAD, or OCD received 16 sessions of treatment and patients with a 
principal diagnosis of PD/A received 12 sessions. Treatment sessions were approximately 
50-60 minutes except for patients with a principal diagnosis of OCD, for whom treatment 
sessions were 80-90 minutes. 
Unified Protocol 
 The UP contains strategies similar to those in the SDPs including cognitive 
reappraisal and exposure, but the focus is on reactions to emotion experience itself, such 
as autonomal arousal rather than situational factors, e.g. crowds.17, 34 The UP consists of 
five core treatment modules: a) mindful emotion awareness; b) cognitive flexibility; c) 
identifying and preventing patterns of emotion avoidance; d) increasing awareness and 
tolerance of emotion-related physical sensations; and e) interoceptive and situational 
emotion-focused exposures. The five core modules are preceded by a module focused on 
enhancing motivation as well as an introductory module on the adaptive nature of 
emotions that provides a framework for understanding emotional experiences.  
Therapists and Treatment Integrity 
Therapists for the study included doctoral students in clinical psychology with 
two to four years of experience, postdoctoral fellows with five to six years of experience, 
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and licensed psychologists with ten or more years of experience. Each therapist 
administered both types of treatment in approximately equal proportions. Initial training 
and certification in the treatment protocols utilized procedures employed in clinical trials 
at CARD over the last 20 years.35 Twenty percent of treatment sessions were randomly 
selected and rated for adherence and competence by an external team of expert raters 
associated with development of the specific treatments using standardized adherence 
ratings approved by the respective protocol developers. Treatment fidelity scores were 
good to excellent (mean: UP = 4.44; SDPs = 4.09 out of 5). 
Assessments and Instruments 
Patients were assessed for current DSM diagnoses using the Anxiety Disorders 
Interview Schedule (ADIS36, 37), a semi-structured clinical interview that focuses on DSM 
diagnoses of anxiety, mood, somatic symptom, and substance use disorders, with 
screening for other disorders. Diagnoses are assigned a dimensional clinical severity 
rating (CSR) on a scale from 0 (no symptoms) to 8 (extremely severe symptoms), with a 
rating of 4 or above (definitely disturbing/disabling) representing the clinical threshold 
for DSM diagnostic criteria.1 The ADIS CSR was assessed by study evaluators blinded to 
condition allocation, and served as the primary outcome for the power analysis and a 
priori specification of the equivalence margin. To maintain interrater reliability 
throughout the trial, a study evaluator was randomly selected each month to rate an 
audiotaped assessment conducted by another evaluator; rated assessments were equally 
                                               1	Due to the introduction of DSM-5 partway through the trial, 168 patients (75%) were 
assigned diagnoses based on DSM-IV criteria and 55 patients (25%) were assigned 
diagnoses based on DSM-5 criteria. To standardize clinical severity ratings across these 
phases, an additional rating was assigned to overall PD/A symptoms for those patients 
diagnosed according to DSM-5, despite the separation of panic disorder and agoraphobia 
in DSM-5.	
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distributed across principal diagnoses and time points. Using criteria specified in Brown 
et al.,38 interrater agreement was 98% for principal diagnosis ADIS CSR. 
Clinical response was assessed using the clinician-rated Clinical Global 
Impression Severity (CGI-S) and Improvement Scales (CGI-I).39 General symptoms of 
anxiety and depression were assessed using the clinician-rated Hamilton Anxiety Rating 
Scale40 and the Hamilton Rating Scale for Depression41 in accordance with the Structured 
Interview Guide for the Hamilton Anxiety and Depression Rating Scale (SIGH-A and 
SIGH-D).42,43 Self-reported outcomes included the Overall Anxiety Severity and 
Impairment Scale (OASIS)44 and Overall Depression Severity and Impairment Scale 
(ODSIS).45 In addition, self-reported interference in the areas of work, home 
management, private leisure, social leisure, and family relationships was assessed with 
the Work and Social Adjustment Scale (WSAS).46,47 Additional clinician-rated measures 
were used to assess diagnosis-specific symptom outcomes and these results are presented 
in eTables 1-3. Patients were assessed at baseline, following every four treatment 
sessions (i.e., after sessions 4, 8, 12), posttreatment (i.e., after session 16), and at 6-month 
follow-up.  
Sample Size Calculation 
Power calculations were performed using SAS PROC POWER48 for the primary 
aims of 1) evaluating equivalence of the UP and SDPs, and 2) evaluating the efficacy of 
the UP and SDPs relative to a benchmark WLC, and were based on conventional target 
values of power = 0.80 and alpha = 0.05. Using an allocation ratio of 2:1 for active 
treatment to WLC groups, results of the power calculations indicated that a sample size 
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of 91 per active treatment group provided adequate power for the analyses of both 
equivalence and superiority. 
Statistical Analysis 
All analyses were conducted with Mplus 7.249 on the intent-to-treat sample that 
included all randomized patients (i.e., 88 patients for the UP, 91 for the SDP, and 44 for 
the WLC conditions, respectively). Missing data were accommodated using multiple 
imputation (10000 imputed datasets) and robust maximum likelihood methods under a 
missing at random assumption. Between-condition effect sizes (Cohen’s d) were 
calculated for each condition comparison using the imputed data.  
The principal hypothesis of equivalence was evaluated using slope difference 
scores from latent growth models (LGM) with treatment condition as a predictor of slope. 
The intercept was centered on the baseline assessment, the intermediate slope loadings 
were freely estimated, and the final slope loading was fixed at 1.0. Slopes therefore 
represented total change from baseline to post-treatment (or follow-up) and could reflect 
nonlinear trajectories of change. Model fit was evaluated based on the confirmatory fit 
index (CFI; ≥  0.90). The equivalence margin of 0.75 ADIS CSR units was selected based 
on available meta-analytic reviews of CBT outcome studies50 and recommendations for 
selecting a priori equivalence limits.51 A priori calculations determined that the 0.75 
ADIS CSR margin corresponded with changes of 0.61 and 0.64 units at posttreatment on 
the SIGH-A and SIGH-D, respectively, and was selected as this difference or less would 
not represent a clinically meaningful difference between two treatments that would lead 
us to prefer one over the other. If the entire confidence interval for the observed mean 
difference between the UP and SDPs falls within the zone of equivalence (-0.75, +0.75), 
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the two treatments would be determined equivalent. To minimize inflation of type I error, 
comparisons among conditions were based primarily on the interpretation of confidence 
intervals and effect sizes. 
To compare the UP and SDPs on other outcomes and to evaluate the UP and 
SDPs relative to the WLC, a 95% CI of between-condition effect sizes from LGM was 
utilized. Treatment response rates were evaluated by comparing the percentage of 
individuals in each condition who no longer met diagnostic criteria for their principal 
diagnosis (i.e., ADIS CSR ≤ 3) and by calculating the relative risk (RR) effect size with 
95% CI. As an exploratory analysis, the percentage of individuals who no longer met 
diagnostic criteria for any emotional disorder (i.e., principal or comorbid) was also 
examined in each condition. 
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RESULTS 
Sample Characteristics 
Table 1 contains demographic and baseline diagnostic characteristics of patients 
within and across conditions. Most patients met criteria for at least one comorbid 
diagnosis (188 [84.3]) and the mean (SD) number of comorbid diagnoses was 2.29 
(1.80). There were no differences in clinical severity or prevalence of comorbid 
disorders. The only demographic difference at baseline was that the WLC condition had a 
higher rate of married patients than the UP or SDP conditions (χ2 = 10.97, p =.002).  
Treatment Credibility and Attrition 
There were no statistically significant differences in patients’ ratings of perceived 
credibility or expectancy between the UP and SDP conditions, as measured by ratings on 
the Credibility/ Expectancy Questionnaire.52 Patients in the UP condition (87.5%) were 
more likely to be classified as treatment completers (i.e., ≥ 75% of sessions completed) 
than patients in the SDP condition (69.2%; odds ratio, 3.11; 95% CI, 1.44 to 6.74).  
Equivalence 
Slope difference scores and between-condition effect sizes for all outcomes from 
the LGM are presented in Table 2. Results of the LGM for principal diagnosis CSR were 
used to examine the primary research question of statistical equivalence of the UP and 
SDPs. The estimate of the UP vs SDPs effect on the slope of change in principal 
diagnosis CSR from baseline to posttreatment was 0.25 (95% CI, -0.26 to 0.75); from 
baseline to follow-up was 0.16 (95% CI, -0.39 to 0.70). The confidence intervals for the 
changes in CSR fell entirely within the pre-specified equivalence criteria of +/- 0.75 CSR 
units and therefore support the hypothesis of statistical equivalence of the UP vs SDPs 
16 
when collapsing across diagnoses at both posttreatment and 6-month follow-up (Figure 
2). The effect size (Cohen’s d) difference for the slope of change in principal diagnosis 
from baseline to posttreatment was 0.15 (95% CI, -0.16 to 0.46); from baseline to follow-
up was 0.10 (95% CI, -0.24 to 0.44).  
Additional Clinician-Rated and Self-Reported Outcomes 
The imputed means and between-condition effect sizes for the primary outcome, 
as well as other additional outcomes of interest are reported in Table 3. Consistent with 
hypotheses, the UP and SDPs each demonstrated superior effects to the WLC on both 
clinician-rated and self-reported outcomes of anxiety and depression based on the 
confidence intervals of the effect sizes. Effect sizes for comparisons of the UP vs SDPs at 
posttreatment and follow-up for all clinical outcomes were generally small and 
statistically non-significant; these findings were consistent across both the LGM-derived 
slope difference scores (Table 2) and effect sizes (Table 3). Change score means and 
within-condition effect sizes are reported in eTable 4. 
Treatment Response and Remission 
At posttreatment, 64% of patients in the UP condition no longer met diagnostic 
criteria for their principal diagnosis, compared to 57% and 27% in the SDP and WLC 
conditions, respectively. For the UP and SDP conditions, these percentages increased to 
71% and 62%, respectively, at 6-month follow-up. The UP (RR = 2.38; 95% CI, 1.42 to 
3.98) and SDP (RR = 2.15; 95% CI, 1.27 to 3.61) conditions were both associated with a 
significantly greater proportion of patients no longer meeting diagnostic criteria for their 
principal diagnosis than in the WLC condition.  
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As an exploratory analysis, we also examined the proportion of individuals who 
no longer met diagnostic criteria for any emotional disorder following treatment. At 
posttreatment, 62% of individuals in the UP condition no longer met diagnostic criteria 
for any emotional disorder, compared to 47% and 13% in the SDP and WLC conditions, 
respectively. These percentages decreased slightly to 57% and 41% for the UP and SDP 
conditions at 6-month follow-up.  
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DISCUSSION 
Results indicated treatment equivalence of the UP and four different SDPs on 
changes in principal diagnosis severity at both posttreatment and 6-month follow-up, with 
the UP evidencing significantly less attrition than the SDPs possibly due to the inclusion 
of strategies for enhancing motivation. Treatment with both the UP and SDPs was 
consistently associated with improved outcomes relative to WLC on clinician-rated and 
self-reported outcomes. Also, relative to the WLC, patients receiving either the UP or 
SDPs had a greater chance of no longer meeting criteria for their principal diagnosis at 
posttreatment.  
These findings provide support for the utility of a parsimonious, mechanism-
focused transdiagnostic approach consisting of five core modules for addressing the most 
commonly occurring mental disorders. The present study also demonstrates that patients 
with diverse diagnoses view a transdiagnostic approach to be as credible as SDPs, which 
is an important consideration given the increasing emphasis on patient preferences in the 
implementation of EBPTs53 and the finding that patients generally prefer psychosocial 
treatment options to other approaches.54 
Clinical trials are commonly criticized for failing to replicate the comorbidity and 
clinical complexity that clinicians encounter in real-world settings.55-57 However, 
inclusion criteria for this trial were liberal, including the full range of comorbid disorders 
thus allowing for significant heterogeneity among patients and, consequently, greater 
generalizability of results. Over 50% of patients were on psychotropic medications and 
approximately 30% were receiving non-CBT psychotherapy at the intake which was 
discontinued if the focus was on anxiety. In addition, most patients had received some 
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form of previous treatment that failed to provide significant or lasting symptom 
remission.  
Results from this trial should be interpreted in the context of several limitations. 
Patients in both groups were generally well-educated, and somewhat less depressed than 
comparable samples which may have augmented their ability to benefit from treatment, 
although prior studies have failed to observe consistent effects of education level on 
treatment outcome in anxiety disorders.58 More importantly, the UP was developed at 
CARD (as were three of the four SDPs), and thus it is possible these results may not fully 
generalize to other clinical settings.   
Nevertheless, utilizing a single protocol designed to target temperamental factors 
underlying the development and maintenance of the full range of emotional disorders has 
implications for bridging the science-to-service gap. Training providers in the delivery of 
one protocol that can simultaneously target commonly comorbid disorders may be more 
efficient and cost effective, as providers are adhering to core strategies that can be 
flexibly applied to a range of emotional experiences. Thus, a transdiagnostic approach, 
such as the UP, may decrease known barriers of receiving an EBPT delivered with 
fidelity, at an adequate dose, in a cost- and time-efficient manner.  
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Figure 1. Recruitment Flow Diagram for Unified Protocol (UP) Single-Disorder Protocol (SDP), and Waitlist Control (WLC) 
Conditions.  
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Abbreviations: UP, Unified Protocol; SDP, Single-Disorder Protocol; WLC, waitlist control. 
 
aCompleted treatment indicates that the patient attended at least 75% of allotted number of sessions (i.e., 9 of 12 for PD/A and 12 of 
16 for other principal diagnoses).  
bOne patient with principal PD/A completed 12 sessions but was withdrawn prior to the posttreatment assessment (i.e., completed 
treatment, but was not eligible for posttreatment assessment).  
cOne patient was withdrawn from the study after completing the posttreatment assessment, but prior to 6-month follow-up, so was no 
longer eligible for 6-month follow-up; however, this individual is included in the “eligible for posttreatment and 6-month follow-up” 
classification (n = 78).
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Figure 2. Model-Based Estimates of the Principal Diagnosis ADIS CSR Score Trajectories from Baseline to 6-Month Follow-Up. 
 
 
 
Abbreviations: UP, Unified Protocol; SDP, Single-Disorder Protocol; WLC, waitlist control; ADIS CSR, clinical severity rating for 
principal diagnosis obtained from Anxiety Disorder Interview Schedule. 
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Table 1. Baseline Demographic and Diagnostic Characteristics by Condition. 
 
 
 No. (%)       
   Condition     
 Total  UP  SDP  WLC 
Variable (N = 223)  (n = 88)  (n = 91)  (n = 44) 
Age, mean (SD), y 31.1 (11.0) 31.0 (11.6) 30.4 (10.0) 32.7 (11.9) 
Female sex 124 (55.6)  48 (54.5)  51 (56.0)  25 (56.8) 
Hispanic 17 (7.6)  3 (3.4)  12 (13.2)  2 (4.5) 
Race        
  White 186 (83.4)  73 (83.0)  76 (83.5)  37 (84.1) 
  Asian 16 (7.2)  6 (6.8)  6 (6.6)  4 (9.1) 
  African American 15 (6.7)  8 (9.1)  5 (5.5)  2 (4.5) 
  Other 6 (2.6)  1 (1.1)  4 (4.4)  1 (2.3) 
Married 47 (21.1)  14 (15.9)  15 (16.5)  18 (40.9)a 
College degree or greater 149 (66.8)  50 (56.8)  63 (69.2)  36 (81.8) 
Current psychotropic medication 121 (54.3)  47 (53.4)  53 (58.2)  21 (47.7) 
Current psychotherapy 65 (29.1)  32 (36.4)  22 (24.2)  11 (25.0) 
Previous psychiatric hospitalization 32 (14.3)  11 (12.5)  15 (16.5)  6 (13.6) 
Principal diagnosis        
  OCD 44 (19.7)  18 (20.5)  17 (18.7)  9 (20.5) 
  GAD 62 (27.8)  22 (25.0)  27 (29.7)  13 (29.5) 
  P/DA 59 (26.5)  25 (28.4)  22 (24.2)  12 (27.3) 
  SAD 58 (26.0)  23 (26.1)  25 (27.5)  10 (22.7) 
Comorbid diagnosesb        
  Any 188 (84.3)  72 (81.8)  78 (85.7)  38 (86.4) 
  OCD 15 (6.7)  3 (3.4)  10 (11.0)  2 (4.5) 
  GAD 40 (17.9)  11 (12.5)  20 (22.0)  9 (20.5) 
  P/DA 12 (5.2)  3 (3.4)  5 (5.5)  4 (9.1) 
  SAD 55 (24.7)  23 (26.1)  20 (22.0)  12 (27.3) 
  MDD 31 (13.9)  12 (13.6)  9 (9.9)  10 (22.7) 
  SP 36 (16.1)  15 (17.0)  14 (15.4)  7 (15.9) 
 
Abbreviations: UP, Unified Protocol; SDP, single-disorder protocol; WLC, waitlist 
control; OCD, obsessive-compulsive disorder; GAD, generalized anxiety disorder; P/DA, 
panic disorder with or without agoraphobia; SAD, social anxiety disorder; MDD, major 
depressive disorder; SP, specific phobia. 
 
aSignificantly different using 2-tailed t test at p < .05.  
bComorbid diagnoses that were present in less than 20 cases are not listed separately in 
the table but are included in the “any” comorbid disorder category and the number of 
comorbid disorders. 
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Table 2. Slope Difference Scores and Between-Condition Effect Sizes from Growth Curve Models. 
 
  Slope Difference Score, Mean (95% CI)a   Effect Size, Cohen's d (95% CI)a   
             
Outcome and Visit UP vs WLC  SDP vs WLC  UP vs SDP  UP vs WLC  SDP vs WLC  UP vs SDP 
Primary Clinician-Rated Outcome           
ADIS CSR            
     Posttreatment -1.51 (-2.14 to -0.87) -1.75 (-2.40 to -1.10) 0.25 (-0.26 to 0.75) -0.93 (-1.29 to -0.57) -1.08 (-1.43 to -0.73) 0.15 (-0.16 to 0.46) 
     6-mo Follow-up    0.16 (-0.39 to 0.70)    0.10 (-0.24 to 0.44) 
Additional Clinician-Rated Outcomes 
CGI-S 
          
     Posttreatment -1.47 (-1.96 to -0.98) -1.40 (-1.90 to -0.91) -0.07 (-0.46 to 0.32) -1.36 (-1.76 to -0.97) -1.30 (-1.70 to -0.90) -0.06 (-0.43 to 0.30) 
     6-mo Follow-up    -0.05 (-0.45 to 0.36)    -0.05 (-0.45 to 0.36) 
CGI-I             
     Posttreatment -1.20 (-1.67 to -0.73) -1.06 (-1.53 to -0.59) -0.14 (-0.50 to 0.22) -1.54 (-2.18 to -0.90) -1.36 (-2.01 to -0.71) -0.18 (-0.64 to 0.28) 
     6-mo Follow-up    -0.07 (-0.41 to 0.26)    -0.06 (-0.31 to 0.20) 
SIGH-A             
     Posttreatment -4.90 (-7.91 to -1.88) -6.86 (-9.83 to -3.89) 1.96 (-0.41 to 4.34) -0.86 (-1.37 to -0.36) -1.21 (-1.68 to -0.74) 0.35 (-0.07 to 0.76) 
     6-mo Follow-up    2.09 (-0.37 to 4.55)    0.35 (-0.05 to 0.74) 
SIGH-D             
     Posttreatment -3.59 (-6.09 to -1.09) -3.53 (-6.01 to -1.04) -0.06 (-2.05 to 1.92) -1.20 (-2.16 to -0.24) -1.18 (-2.12 to -0.23) -0.02 (-0.68 to 0.64) 
     6-mo Follow-up    0.07 (-1.86 to 2.01)    0.02 (-0.46 to 0.50) 
Self-Reported Outcomes           
OASIS             
     Posttreatment -4.25 (-5.68 to -2.82) -4.47 (-5.92 to -3.02) 0.22 (-0.96 to 1.40) -1.39 (-1.82 to -0.95) -1.46 (-1.90 to -1.02) 0.07 (-0.31 to 0.46) 
     6-mo Follow-up    0.37 (-0.81 to 1.55)    0.13 (-0.28 to 0.54) 
ODSIS             
     Posttreatment -1.69 (-3.19 to -0.18) -0.68 (-2.18 to 0.82) -1.01 (-2.19 to 0.17) -0.73 (-1.35 to -0.10) -0.29 (-0.93 to 0.34) -0.44 (-0.94 to 0.07) 
     6-mo Follow-up    -0.55 (-1.77 to 0.67)    -0.20 (-0.65 to 0.25) 
WSAS             
     Posttreatment -6.63 (-9.47 to -3.79) -6.22 (-9.07 to -3.38) -0.41 (-2.65 to 1.83) -1.16 (-1.60 to 0.72) -1.09 (-1.54 to -0.64) -0.07 (-0.46 to 0.32) 
     6-mo Follow-up    -0.47 (-2.77 to 1.84)    -0.08 (-0.50 to 0.33) 
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Abbreviations: UP, Unified Protocol; SDP, single-disorder protocol; WLC, waitlist control; ADIS CSR, clinical severity rating for 
principal diagnosis obtained from Anxiety Disorder Interview Schedule; CGI-S, Clinical Global Impression – Severity Scale; CGI-I, 
Clinical Global Impression – Improvement Scale; SIGH-A, Structured Interview Guide for Hamilton Anxiety Scale; SIGH-D, 
Structured Interview Guide for Hamilton Depression Scale; OASIS, Overall Anxiety Severity and Impairment Scale; ODSIS, Overall 
Depression Severity and Impairment Scale; WSAS, Work and Social Adjustment Scale. 
 
aNegative slope difference scores and effect sizes indicate that the treatment listed first was associated with a greater decrease in the 
outcome. Positive slope difference scores and effect sizes indicate that the treatment listed first was associated with a lesser decrease 
or a greater increase in the outcome.  
 
Slope difference scores and between-condition effect sizes for diagnosis-specific outcomes are reported in eTable 4. 
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Table 3. Means and Between-Condition Effect Sizes of Outcomes. 
 
  Mean (SD)    Effect Size, Hedges g (95% CI)a  
             
  UP  SDP  WLC       
Outcome and Visit (n = 88)  (n = 91)  (n = 44)  UP vs WLC  SDP vs WLC  UP vs SDP 
Primary Clinician-Rated Outcome           
ADIS CSR            
     Baseline 5.41 (0.76) 5.52 (0.80) 5.45 (0.69) -0.05 (-0.41 to 0.31) 0.09 (-0.27 to 0.45) -0.14 (-0.43 to 0.16) 
     Posttreatment 2.99 (1.84) 3.05 (2.02) 4.60 (1.61) -0.91 (-1.29 to -0.53) -0.81 (-1.19 to -0.44) -0.03 (-0.32 to 0.26) 
     6-mo Follow-up 2.73 (1.71) 2.66 (2.06)      0.03 (-0.26 to 0.33) 
Additional Clinician-Rated Outcomes 
CGI-S 
        
     Baseline 4.60 (0.90) 4.74 (0.98) 4.61 (0.71) -0.01 (-0.38 to 0.35) 0.13 (-0.23 to 0.49) -0.14 (-0.44 to 0.15) 
     Posttreatment 3.11 (1.34) 3.15 (1.49) 4.25 (1.15) -0.89 (-1.26 to -0.51) -0.79 (-1.16 to -0.42) -0.03 (-0.32 to 0.26) 
     6-mo Follow-up 3.01 (1.41) 3.01 (1.35)      0.00 (-0.29 to 0.29) 
CGI-I             
     Session 1 3.49 (0.67) 3.49 (0.78) 3.74 (0.97) -0.31 (-0.68 to 0.05) -0.30 (-0.66 to 0.06) 0.01 (-0.28 to 0.30) 
     Posttreatment 2.22 (1.15) 2.39 (1.32) 3.38 (0.98) -1.05 (-1.43 to -0.67) -0.81 (-1.18 to -0.43) -0.14 (-0.43 to 0.16) 
     6-mo Follow-up 2.30 (1.45) 2.21 (1.24)      0.07 (-0.22 to 0.36) 
SIGH-A             
     Baseline 17.06 (8.50) 17.01 (9.51) 16.77 (8.44) 0.03 (-0.33 to 0.40) 0.03 (-0.33 to 0.39) 0.01 (-0.29 to 0.30) 
     Posttreatment 10.38 (8.07) 8.94 (8.08) 14.63 (7.80) -0.53 (-0.90 to -0.16) -0.71 (-1.08 to -0.34) 0.18 (-0.12 to 0.47) 
     6-mo Follow-up 9.94 (7.94) 8.95 (8.49)      0.12 (-0.17 to 0.41) 
SIGH-D             
     Baseline 11.55 (7.02) 11.49 (6.30) 11.82 (6.32) -0.04 (-0.40 to 0.32) -0.05 (-0.41 to 0.31) 0.01 (-0.28 to 0.30) 
     Posttreatment 7.21 (6.12) 7.20 (7.10) 10.76 (6.20) -0.57 (-0.94 to -0.21) -0.52 (-0.88 to -0.15) 0.00 (-0.29 to 0.29) 
     6-mo Follow-up 7.57 (6.79) 6.87 (7.04)      0.10 (-0.19 to 0.39) 
Self-Reported Outcomes           
OASIS             
     Baseline 9.68 (3.81) 10.37 (6.30) 9.62 (3.77) 0.02 (-0.35 to 0.38) 0.13 (-0.23 to 0.49) -0.13 (-0.42 to 0.16) 
     Posttreatment 4.70 (3.18) 4.98 (4.24) 7.91 (4.10) -0.91 (-1.29 to -0.53) -0.70 (-1.07 to -0.33) -0.07 (-0.37 to 0.22) 
     6-mo Follow-up 4.86 (4.03) 4.78 (3.88)      0.02 (-0.27 to 0.31) 
ODSIS             
     Baseline 5.38 (5.14) 5.28 (4.69) 6.09 (5.00) -0.14 (-0.50 to 0.22) -0.17 (-0.53 to 0.19) 0.02 (-0.27 to 0.31) 
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     Posttreatment 2.95 (3.82) 3.11 (4.17) 4.88 (5.09) -0.45 (-0.81 to -0.08) -0.39 (-0.76 to -0.03) -0.04 (-0.33 to 0.25) 
     6-mo Follow-up 3.49 (4.39) 2.65 (3.88)      0.20 (-0.09 to 0.49) 
WSAS             
     Baseline 15.09 (7.36) 15.04 (6.38) 15.55 (6.89) -0.06 (-0.42 to 0.30) -0.08 (-0.44 to 0.28) 0.01 (-0.29 to 0.30) 
     Posttreatment 7.63 (7.61) 7.75 (7.67) 13.58 (7.52) -0.78 (-1.15 to -0.41) -0.76 (-1.13 to -0.39) -0.02 (-0.31 to 0.28) 
     6-mo Follow-up 6.85 (7.07) 6.59 (7.95)      0.03 (-0.26 to 0.33) 
 
Abbreviations: UP, Unified Protocol; SDP, single-disorder protocol; WLC, waitlist control; ADIS CSR, clinical severity rating for 
principal diagnosis obtained from Anxiety Disorder Interview Schedule; CGI-S, Clinical Global Impression – Severity Scale; CGI-I, 
Clinical Global Impression – Improvement Scale; SIGH-A, Structured Interview Guide for Hamilton Anxiety Scale; SIGH-D, 
Structured Interview Guide for Hamilton Depression Scale; OASIS, Overall Anxiety Severity and Impairment Scale; ODSIS, Overall 
Depression Severity and Impairment Scale; WSAS, Work and Social Adjustment Scale. 
 
aNegative effect sizes indicate that the treatment listed first was associated with lower levels of the outcome and positive effect sizes 
indicate that the treatment listed first was associated with higher levels of the outcome.  
 
Means and between-condition effect sizes for diagnosis-specific outcomes are reported in eTable 2. 
 
